<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39381111</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of tofacitinib on COVID-19 patients: A systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e38229</StartPage><MedlinePgn>e38229</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e38229</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e38229</ELocationID><Abstract><AbstractText>The use of drugs off-label for managing COVID-19 offers a potential approach. Among these potential drugs, tofacitinib, a JAK inhibitor, is strongly implicated in its ability to mitigate mortality by attenuating the cytokine storm syndrome. This study systematically reviewed and quantitatively assessed the effectiveness and safety profile of tofacitinib use through meta-analysis. Through searches of the PubMed, Scopus, and the Cochrane Library databases up to May 31, 2024, six articles meeting inclusion criteria were identified, encompassing 669 patients diagnosed with COVID-19. The review findings indicate that tofacitinib use demonstrates significant clinical efficacy, as evidenced by a reduced risk of mortality (P = 0.003), and a decreased need for invasive mechanical ventilation (P = 0.0002). Furthermore, tofacitinib use is not correlated with an increased risk of adverse drug reactions (P = 0.98), indicating a favorable safety profile. In conclusion, the evidence supports the clinical efficacy of tofacitinib for COVID-19 patients without concomitant risks of adverse effects. Further clinical studies, especially larger-scale randomized controlled trials, are necessary to validate the findings of this study.</AbstractText><CopyrightInformation>© 2024 The Authors. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilar</LastName><ForeName>Gofarana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suhandi</LastName><ForeName>Cecep</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, 45363, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukunaga</LastName><ForeName>Kohji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawahata</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Cytokine syndrome</Keyword><Keyword MajorTopicYN="N">Janus kinase inhibitor</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Tofacitinib</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39381111</ArticleId><ArticleId IdType="pmc">PMC11456853</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e38229</ArticleId><ArticleId IdType="pii">S2405-8440(24)14260-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Sen Tan K., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak- A n update on the status. Mil Med Res. 2020;7 doi: 10.1186/s40779-020-00240-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell J.M., Le X., McIntosh L., Meehan M.T., Ogunlade S., Ragonnet R., O'Neill G.K., Trauer J.M., McBryde E.S. Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. Paediatr. Respir. Rev. 2021;39 doi: 10.1016/j.prrv.2021.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2021.07.002</ArticleId><ArticleId IdType="pmc">PMC8294600</ArticleId><ArticleId IdType="pubmed">34417121</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk C., Turk S., Malkan U.Y., Haznedaroglu I.C. Three critical clinicobiological phases of the human SARS-associated coronavirus infections. Eur. Rev. Med. Pharmacol. Sci. 2020;24 doi: 10.26355/eurrev_202008_22660.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202008_22660</ArticleId><ArticleId IdType="pubmed">32894568</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar R.B., Hardigan P., Mayi B., Sider D., Piotrkowski J., Mehta J.P., Dev J., Seijo Y., Camargo A.L., Andux L., Hagen K., Hernandez M.B. Current understanding of COVID-19 clinical course and investigational treatments. Front. Med. 2020;7 doi: 10.3389/fmed.2020.555301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.555301</ArticleId><ArticleId IdType="pmc">PMC7641603</ArticleId><ArticleId IdType="pubmed">33195304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur. Respir. J. 2020;55 doi: 10.1183/13993003.00607-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00607-2020</ArticleId><ArticleId IdType="pmc">PMC7144260</ArticleId><ArticleId IdType="pubmed">32269085</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner T., Wahezi D.M. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. Paediatr. Respir. Rev. 2020;35 doi: 10.1016/j.prrv.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7387280</ArticleId><ArticleId IdType="pubmed">32792288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustine J.N., Jones D. Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol. 2021;191 doi: 10.1016/j.ajpath.2020.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.08.009</ArticleId><ArticleId IdType="pmc">PMC7484812</ArticleId><ArticleId IdType="pubmed">32919977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramatillah D.L., Gan S.H., Pratiwy I., Sulaiman S.A.S., Jaber A.A.S., Jusnita N., Lukas S., Bakar U.A. Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. PLoS One. 2022;17 doi: 10.1371/journal.pone.0262438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262438</ArticleId><ArticleId IdType="pmc">PMC8789122</ArticleId><ArticleId IdType="pubmed">35077495</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidpoor J., Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: interactions and therapeutic applications. Biomed. Pharmacother. 2022;145 doi: 10.1016/j.biopha.2021.112419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112419</ArticleId><ArticleId IdType="pmc">PMC8585600</ArticleId><ArticleId IdType="pubmed">34781146</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Hu K., Li Y., Lu C., Ling K., Cai C., Wang W., Ye D. Targeting TNF-α for COVID-19: recent advanced and controversies. Front. Public Health. 2022;10 doi: 10.3389/fpubh.2022.833967.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.833967</ArticleId><ArticleId IdType="pmc">PMC8873570</ArticleId><ArticleId IdType="pubmed">35223745</ArticleId></ArticleIdList></Reference><Reference><Citation>Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D., Criner G.J., Kaplan-Lewis E., Baden R., Pandit L., Cameron M.L., Garcia-Diaz J., Chávez V., Mekebeb-Reuter M., Lima de Menezes F., Shah R., González-Lara M.F., Assman B., Freedman J., Mohan S.V. Tocilizumab in patients hospitalized with covid-19 pneumonia. N. Engl. J. Med. 2021;384 doi: 10.1056/nejmoa2030340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2030340</ArticleId><ArticleId IdType="pmc">PMC7781101</ArticleId><ArticleId IdType="pubmed">33332779</ArticleId></ArticleIdList></Reference><Reference><Citation>Boppana T.K., Mittal S., Madan K., Mohan A., Hadda V., Guleria R. Tocilizumab for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Monaldi Arch. Chest Dis. 2022;92 doi: 10.4081/monaldi.2022.2136.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2022.2136</ArticleId><ArticleId IdType="pubmed">35130679</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Halloran J.A., Ko E.R., Anstrom K.J., et al. Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA. 2023;330 doi: 10.1001/jama.2023.11043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.11043</ArticleId><ArticleId IdType="pmc">PMC10334296</ArticleId><ArticleId IdType="pubmed">37428480</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangappa P. Cytokine storm and immunomodulation in covid-19. Indian J. Crit. Care Med. 2021;25 doi: 10.5005/jp-journals-10071-24029.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10071-24029</ArticleId><ArticleId IdType="pmc">PMC8608645</ArticleId><ArticleId IdType="pubmed">34866828</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhang Y., Qiao W., Zhang J., Qi Z. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int. Immunopharm. 2020;86 doi: 10.1016/j.intimp.2020.106749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.106749</ArticleId><ArticleId IdType="pmc">PMC7328558</ArticleId><ArticleId IdType="pubmed">32645632</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O., Abbas A., Abbas F., et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400 doi: 10.1016/S0140-6736(22)01109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01109-6</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi V.C., Ramanan A.V., de Bono S., et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9 doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj V., Finn A., Lal A., Khan M.S., Dapaah-Afriyie K., Carino G.P. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;49 doi: 10.1016/j.eclinm.2022.101489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101489</ArticleId><ArticleId IdType="pmc">PMC9163705</ArticleId><ArticleId IdType="pubmed">35677732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chebbi P., Shobha V., Rao V.K., Haridas V., Janardana R., Pinto B., Kumar S., Patil A., Tekkatte R., Salanke M., Mahendranath K.M. Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset. BMC Rheumatol. 2023;7 doi: 10.1186/s41927-023-00345-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-023-00345-8</ArticleId><ArticleId IdType="pmc">PMC10369741</ArticleId><ArticleId IdType="pubmed">37496101</ArticleId></ArticleIdList></Reference><Reference><Citation>Maslennikov R., Ivashkin V., Vasilieva E., Chipurik M., Semikova P., Semenets V., Russkova T., Levshina A., Grigoriadis D., Magomedov S., Efremova I., Dzhakhaya N. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19. Pulm. Pharmacol. Ther. 2021;69 doi: 10.1016/j.pupt.2021.102039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2021.102039</ArticleId><ArticleId IdType="pmc">PMC8137353</ArticleId><ArticleId IdType="pubmed">34023513</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Liberati A., Tetzlaff J., Altman D.G., Antes G., Atkins D., Barbour V., Barrowman N., Berlin J.A., Clark J., Clarke M., Cook D., D'Amico R., Deeks J.J., Devereaux P.J., Dickersin K., Egger M., Ernst E., Gøtzsche P.C., Grimshaw J., Guyatt G., Higgins J., Ioannidis J.P.A., Kleijnen J., Lang T., Magrini N., McNamee D., Moja L., Mulrow C., Napoli M., Oxman A., Pham B., Rennie D., Sampson M., Schulz K.F., Shekelle P.G., Tovey D., Tugwell P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6 doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian J., Zhang J., Ge L., Yang K., Song F. The methodological and reporting quality of systematic reviews from China and the USA are similar. J. Clin. Epidemiol. 2017;85 doi: 10.1016/j.jclinepi.2016.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2016.12.004</ArticleId><ArticleId IdType="pubmed">28063911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Tian J., Tian H., Moher D., Liang F., Jiang T., Yao L., Yang K. Network meta-analyses could be improved by searching more sources and by involving a librarian. J. Clin. Epidemiol. 2014;67 doi: 10.1016/j.jclinepi.2014.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.04.003</ArticleId><ArticleId IdType="pubmed">24841794</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu-Xia L., Ya Z., Yao-Long C., Ke-Hu Y., Zong-Jiu Z. The reporting characteristics and methodological quality of Cochrane reviews about health policy research. Health Pol. 2015;119 doi: 10.1016/j.healthpol.2014.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2014.09.002</ArticleId><ArticleId IdType="pubmed">25260911</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins J.P.T., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., Savović J., Schulz K.F., Weeks L., Sterne J.A.C. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Online) 2011;343 doi: 10.1136/bmj.d5928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells G., Shea B., O'Connell D., Peterson J., Welch V., Losos M., Tugwell P. He Newcastle–Ottawa Scale (NOQAS) for Assessing the Quality of Non-randomized Studies in Meta-Analysis, The Ottawa Hospital. 2004. T.</Citation></Reference><Reference><Citation>Higgins J.P.T., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 2003;327 doi: 10.1136/bmj.327.7414.557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau J., Ioannidis J.P.A., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. Br. Med. J. 2006;333 doi: 10.1136/bmj.333.7568.597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.333.7568.597</ArticleId><ArticleId IdType="pmc">PMC1570006</ArticleId><ArticleId IdType="pubmed">16974018</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P.K., Lalwani L.K., Govindagoudar M.B., Aggarwal R., Chaudhry D., Kumar P., Gehlaut P. Tofacitinib associated with reduced intubation rates in the management of severe covid-19 pneumonia: a preliminary experience. Indian J. Crit. Care Med. 2021;25 doi: 10.5005/jp-journals-10071-23964.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10071-23964</ArticleId><ArticleId IdType="pmc">PMC8645820</ArticleId><ArticleId IdType="pubmed">34916741</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugesan H., Cs G., Nasreen H.S., Santhanam S., M G., Ravi S., Es S.S. An evaluation of efficacy and safety of tofacitinib, A JAK inhibitor in the management of hospitalized patients with mild to moderate COVID-19 - an open-label randomized controlled study. J. Assoc. Phys. India. 2022;69</Citation><ArticleIdList><ArticleId IdType="pubmed">35057599</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrarini A., Vacca A., Solimando A.G., Tavio M., Acquaviva R., Rocchi M., Nitti C., Salvi A., Menditto V., Luchetti Gentiloni M.M., Russo A., Moretti M., Pavani M., Giacometti A., Bonifazi M., Zuccatosta L., Romani L., Racanelli V., Moroncini G., Gabrielli A., Pomponio G. Early administration of tofacitinib in COVID-19 pneumonitis: an open randomised controlled trial. Eur. J. Clin. Invest. 2023;53 doi: 10.1111/eci.13898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13898</ArticleId><ArticleId IdType="pubmed">36380693</ArticleId></ArticleIdList></Reference><Reference><Citation>Almasi S., Rashidi A., Kachuee M.A., Shirazi B.M., Izadi S., Ghaffarpour S., Azimi M., Naghizadeh M.M., Makiani M.J., Ranjbar M., Goudarzi M., Rahimian N., Ghazanfari T. Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19. Int. Immunopharm. 2023;122 doi: 10.1016/j.intimp.2023.110565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2023.110565</ArticleId><ArticleId IdType="pubmed">37454635</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimarães P.O., Quirk D., Furtado R.H., Maia L.N., Saraiva J.F., Antunes M.O., Kalil Filho R., Junior V.M., Soeiro A.M., Tognon A.P., Veiga V.C., Martins P.A., Moia D.D.F., Sampaio B.S., Assis S.R.L., Soares R.V.P., Piano L.P.A., Castilho K., Momesso R.G.R.A.P., Monfardini F., Guimarães H.P., Ponce de Leon D., Dulcine M., Pinheiro M.R.T., Gunay L.M., Deuring J.J., Rizzo L.V., Koncz T., Berwanger O. Tofacitinib in patients hospitalized with covid-19 pneumonia. N. Engl. J. Med. 2021;385 doi: 10.1056/nejmoa2101643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2101643</ArticleId><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims J.T., Krishnan V., Chang C.Y., Engle S.M., Casalini G., Rodgers G.H., Bivi N., Nickoloff B.J., Konrad R.J., de Bono S., Higgs R.E., Benschop R.J., Ottaviani S., Cardoso A., Nirula A., Corbellino M., Stebbing J. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J. Allergy Clin. Immunol. 2021;147 doi: 10.1016/j.jaci.2020.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.08.031</ArticleId><ArticleId IdType="pmc">PMC7488591</ArticleId><ArticleId IdType="pubmed">32920092</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow-Pay F., Htut T.W., Khezrian M., Myint P.K. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf. 2021;12 doi: 10.1177/2042098620985687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2042098620985687</ArticleId><ArticleId IdType="pmc">PMC7882764</ArticleId><ArticleId IdType="pubmed">33628418</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng J., Fu M., Mei H., Zheng H., Liang G., She X., Wang Q., Liu W. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis. Rev. Med. Virol. 2022;32 doi: 10.1002/rmv.2295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2295</ArticleId><ArticleId IdType="pmc">PMC8646369</ArticleId><ArticleId IdType="pubmed">34558756</ArticleId></ArticleIdList></Reference><Reference><Citation>Seif F., Aazami H., Khoshmirsafa M., Kamali M., Mohsenzadegan M., Pornour M., Mansouri D. JAK inhibition as a new treatment strategy for patients with COVID-19. Int. Arch. Allergy Immunol. 2020;181 doi: 10.1159/000508247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000508247</ArticleId><ArticleId IdType="pmc">PMC7270061</ArticleId><ArticleId IdType="pubmed">32392562</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Zhou Y.H., Yang Z.Q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell. Mol. Immunol. 2016;13 doi: 10.1038/cmi.2015.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2015.74</ArticleId><ArticleId IdType="pmc">PMC4711683</ArticleId><ArticleId IdType="pubmed">26189369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoisnard L., Lebrun-Vignes B., Maury S., Mahevas M., El Karoui K., Roy L., Zarour A., Michel M., Cohen J.L., Amiot A., Claudepierre P., Wolkenstein P., Grimbert P., Sbidian E. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci. Rep. 2022;12 doi: 10.1038/s41598-022-10777-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10777-w</ArticleId><ArticleId IdType="pmc">PMC9065106</ArticleId><ArticleId IdType="pubmed">35504889</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., chun Luo Z. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin. Rheumatol. 2019;38 doi: 10.1007/s10067-018-4299-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-018-4299-4</ArticleId><ArticleId IdType="pubmed">30242639</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y.K., Song J., Kim K., Kwon J.W. Potential adverse events reported with the Janus kinase inhibitors approved for the treatment of rheumatoid arthritis using spontaneous reports and online patient reviews. Front. Pharmacol. 2022;12 doi: 10.3389/fphar.2021.792877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.792877</ArticleId><ArticleId IdType="pmc">PMC8787189</ArticleId><ArticleId IdType="pubmed">35087406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>